The antiproliferative effects of PPARgamma ligands in normal human mammary epithelial cells. Breast Cancer Res Treat 2003 Mar;78(2):179-92
Date
05/03/2003Pubmed ID
12725418DOI
10.1023/a:1022978608125Abstract
Peroxisome proliferator-activated receptor gamma (PPARgamma) is a transcription factor in the steroid nuclear receptor superfamily. Ligand activation of PPARgamma is associated with differentiation and an inhibition of proliferation in normal and malignant cells, including adipocytes, monocytes, and tumor cells in colon, prostate, and breast cancers. The current studies were undertaken to assess both the expression and functional activity of PPARgamma in cultured normal human mammary epithelial cells (HMECs) and tissue samples. Analyses by northern hybridization, immunoblotting, and immunohistochemistry demonstrate PPARgamma gene expression in HMECs and breast tissue specimens. DNA binding and transactivation assays indicate the presence of functionally active PPARgamma in HMECs. Treatment with PPARgamma selective ligands, 15-deoxy-delta-(12,14)-prostaglandin J2 (15dPGJ2) and ciglitazone, inhibits the growth of HMECs in a dose-dependent manner. This growth inhibition is associated with alterations in cell cycle progression and the induction of apoptosis.
Author List
Yee LD, Guo Y, Bradbury J, Suster S, Clinton SK, Seewaldt VLMESH terms used to index this publication - Major topics in bold
ApoptosisBreast
Cell Cycle
Cell Division
Cells, Cultured
Epithelial Cells
Female
Gene Expression
Humans
Hypoglycemic Agents
Ligands
Prostaglandin D2
Receptors, Cytoplasmic and Nuclear
Repressor Proteins
Thiazoles
Thiazolidinediones
Transcription Factors
